Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on May 22, 2025
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire
·
May 22, 2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its …
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
GlobeNewswire
·
May 22, 2025
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. – NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) – …
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire
·
May 22, 2025
ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an …
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
GlobeNewswire
·
May 22, 2025
Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002). Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontinuations due to …
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment
GlobeNewswire
·
May 22, 2025
New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA interference (RNAi) therapies targeting KRAS-driven cancers. The …
Recode Ventures' Vishal Gulati Elected Fellow Of Academy Of Medical Sciences For Contributions To Translational Medicine
EIN Presswire
·
May 22, 2025
Healthcare Venture Capitalist Vishal Gulati Inducted Into The Academy Of Medical Sciences In Recognition Of His Role In Translational Medicine. LONDON, UK, UNITED KINGDOM, May 22, 2025 /EINPresswire.com/ -- Recode Ventures is honoured to announce that …
Houston Emerges as Global Center for Brain Health Innovation
GlobeNewswire
·
May 22, 2025
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Protecting and enriching human brain health and performance may be one of the most important economic strategies that businesses and governments pursue as they seek to strengthen workforces, mitigate the surging …
Endurance Bio Inc. Announces Selection of T-168 for Neuro-SysMed’s SLEIPNIR Platform Trial in Parkinson’s Disease
GlobeNewswire
·
May 22, 2025
SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its compound, T-168, has been selected for testing on …
Newly Formed National Alliance Aims to Help Cities and States Combat Opioid Crisis and Improve Public Health Outcomes
GlobeNewswire
·
May 22, 2025
Milwaukee, Wis., May 22, 2025 (GLOBE NEWSWIRE) -- In a timely effort to address the nation’s opioid epidemic, CMRignite, one of the nation’s leading cause marketing agencies, has launched a new national recovery alliance composed of trusted messengers, …
Celebrating 10 Years of National Deafblind Awareness Month in Canada
GlobeNewswire
·
May 22, 2025
Newmarket, Ontario, Canada, May 22, 2025 (GLOBE NEWSWIRE) -- June 2025 marks a significant milestone—10 years since the Senate of Canada officially proclaimed June as National Deafblind Awareness Month. This anniversary is a powerful opportunity to …
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
GlobeNewswire
·
May 22, 2025
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement Healthcare …
Global Lentiviral Vector Market Outlook 2025–2034: Drivers, Trends, Opportunities, and Growth Forecast
EIN Presswire
·
May 22, 2025
The Business Research Company's Global Lentiviral Vector Market Outlook 2025–2034: Drivers, Trends, Opportunities, and Growth Forecast LONDON, GREATER LONDON, UNITED KINGDOM, May 22, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest …
Global Healthcare Staffing Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
EIN Presswire
·
May 22, 2025
The Business Research Company’s Healthcare Staffing Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 22, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report …
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
GlobeNewswire
·
May 22, 2025
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion …
CareSource and Three Square Food Bank unite to tackle hunger in Southern Nevada
GlobeNewswire
·
May 22, 2025
LAS VEGAS, May 22, 2025 (GLOBE NEWSWIRE) -- Today, CareSource Nevada, a nonprofit managed care organization recently selected to implement Nevada’s Medicaid Managed Care Program, awarded Three Square Food Bank a $10,000 donation and a Heart of the …
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
GlobeNewswire
·
May 22, 2025
WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders …
Global High-Throughput Screening Market Poised for Strong Growth, Hitting $39.2 Billion by 2029
GlobeNewswire
·
May 22, 2025
Boston, May 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “High-Throughput Screening: Technologies and Global Markets” is expected to grow from $23.8 billion in 2024 to $39.2 billion by the end of 2029 at a compound annual …
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
GlobeNewswire
·
May 22, 2025
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Global Foley Catheters Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight
GlobeNewswire
·
May 22, 2025
New York, USA, May 22, 2025 (GLOBE NEWSWIRE) -- Global Foley Catheters Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight The growing demand for Foley catheters is driven by several important factors. Firstly, the …
Hypofibrinogenemia Market Set to Grow as New Treatments Emerge During the Forecast Period (2025–2034) | DelveInsight
GlobeNewswire
·
May 22, 2025
New York, USA, May 22, 2025 (GLOBE NEWSWIRE) -- Hypofibrinogenemia Market Set to Grow as New Treatments Emerge During the Forecast Period (2025–2034) | DelveInsight DelveInsight projects a promising growth trajectory for the hypofibrinogenemia market …